TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) and Tr...

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC) and TransMedics Group (TMDX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TransMedics Group (TMDX – Research Report) and Ste...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (TMDX) and Steris (STE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ImmunityBio (IBRX – Research Report) and TransMedics...

Analysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX) and TransMedics Group (TMDX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marker Therapeutics (MRKR – Research Report), Pasith...

Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TransMedics Group (TMDX – Research Report), Beam T...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (TMDX), Beam Therapeutics (BEAM) and Boston Scientific (BSX)

Transmedics Group ($TMDX) announced an update on their ongoing clinical study. Study Overview: The “Decreasing Edema With a Novel OCS Solution (DEN...

TransMedics’ DENOVO Trial: New Lung Preservation Study Could Shape Future Growth for TMDX

TransMedics Group ( ($TMDX) ) has issued an update. On January 8, 2026, TransMedics Group entered into a long-term lease with BioMed Realty for app...

TransMedics Group Expands Somerville Campus With Major Lease

Stifel Nicolaus analyst Thomas Stephan reiterated a Hold rating on TransMedics Group today and set a price target of $115.00. Stephan covers the He...

Current Quarter	$0.41	Next Quarter	$0.66
Current Year	$2.61	Next Year	$2.71
QoQ Growth	+61.0%	YoY Growth	+3.8%
3Y EPS CAGR	+38.7%	Target Price	$144.73
Consensus	Buy	Upside	+6.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TMDX	$135.50	+1.13%	363.31K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TMDX	$135.50	+1.1%	363.31K
3
4
5
6

TMDX

TMDX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get TransMedics Group Inc. Data in Excel

Get TransMedics Group Inc. Data in Excel